BR112013001978A2 - derivados de anticâncer, preparação dos mesmos e uso terapêutico dos mesmos - Google Patents

derivados de anticâncer, preparação dos mesmos e uso terapêutico dos mesmos

Info

Publication number
BR112013001978A2
BR112013001978A2 BR112013001978A BR112013001978A BR112013001978A2 BR 112013001978 A2 BR112013001978 A2 BR 112013001978A2 BR 112013001978 A BR112013001978 A BR 112013001978A BR 112013001978 A BR112013001978 A BR 112013001978A BR 112013001978 A2 BR112013001978 A2 BR 112013001978A2
Authority
BR
Brazil
Prior art keywords
preparation
therapeutic use
anticancer
derivatives
anticancer derivatives
Prior art date
Application number
BR112013001978A
Other languages
English (en)
Other versions
BR112013001978B1 (pt
Inventor
Alain Commerçon
Laurence Gauzy-Lazo
Philippe Hubert
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43027561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013001978(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112013001978A2 publication Critical patent/BR112013001978A2/pt
Publication of BR112013001978B1 publication Critical patent/BR112013001978B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

derivados de anticâncer, preparação dos mesmos e uso terapêutico dos mesmos. a presente invenção refere-se aos conjugados de dímeros de pirrolo[1,4]benzodiazepina (pbd), às composições contendo-os e ao seu uso terapêutico, especialmente como agentes anticâncer. a invenção também se refere ao processo para a preparação dos conjugados e ao seu uso como agentes anticâncer,e também aos dímeros sozinhos. a fórmula (l) na qual: representa uma ligação única ou uma ligação dupla.
BR112013001978-6A 2010-07-26 2011-07-25 Compostos e conjugados de derivados de anticâncer, processo de preparação dos conjugados e uso terapêutico dos mesmos BR112013001978B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1056103A FR2963007B1 (fr) 2010-07-26 2010-07-26 Derives anticancereux, leur preparation et leur application therapeutique
FR1056103 2010-07-26
PCT/IB2011/053310 WO2012014147A1 (en) 2010-07-26 2011-07-25 Anticancer derivatives, preparation thereof and therapeutic use thereof

Publications (2)

Publication Number Publication Date
BR112013001978A2 true BR112013001978A2 (pt) 2016-05-24
BR112013001978B1 BR112013001978B1 (pt) 2020-03-03

Family

ID=43027561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001978-6A BR112013001978B1 (pt) 2010-07-26 2011-07-25 Compostos e conjugados de derivados de anticâncer, processo de preparação dos conjugados e uso terapêutico dos mesmos

Country Status (30)

Country Link
US (1) US9056914B2 (pt)
EP (1) EP2598507B1 (pt)
JP (1) JP5814366B2 (pt)
KR (1) KR20130094806A (pt)
CN (1) CN103140491B (pt)
AR (1) AR082341A1 (pt)
AU (1) AU2011284339B2 (pt)
BR (1) BR112013001978B1 (pt)
CA (1) CA2806665A1 (pt)
CL (1) CL2013000250A1 (pt)
CO (1) CO6650375A2 (pt)
CR (1) CR20130035A (pt)
DO (1) DOP2013000021A (pt)
EA (1) EA201390162A1 (pt)
EC (1) ECSP13012404A (pt)
ES (1) ES2638520T3 (pt)
FR (1) FR2963007B1 (pt)
GT (1) GT201300025A (pt)
MA (1) MA34469B1 (pt)
MX (1) MX2013001069A (pt)
MY (1) MY159197A (pt)
NI (1) NI201300010A (pt)
NZ (1) NZ606246A (pt)
PE (1) PE20130489A1 (pt)
SG (1) SG187191A1 (pt)
TW (1) TW201208689A (pt)
UA (1) UA111164C2 (pt)
UY (1) UY33531A (pt)
WO (1) WO2012014147A1 (pt)
ZA (1) ZA201300685B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CN105307685B (zh) * 2013-03-13 2019-03-08 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
CN105142674B (zh) * 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
ES2830385T3 (es) 2014-09-12 2021-06-03 Genentech Inc Anticuerpos e inmunoconjugados anti-HER2
CA2957148A1 (en) * 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
TW201632531A (zh) 2015-01-14 2016-09-16 必治妥美雅史谷比公司 苯二氮呯二聚物，其結合物及製造與使用方法
BR112017014937A2 (pt) 2015-01-14 2018-03-13 Bristol-Myers Squibb Company dímeros de benzodiazepina ligados em ponte a heteroarileno, conjugados dos mesmos, e métodos de preparação e uso
EP3313854A1 (en) 2015-06-23 2018-05-02 Bristol-Myers Squibb Company Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
DK3612537T3 (da) 2017-04-18 2022-08-08 Medimmune Ltd Pyrrolobenzodiazepinkonjugater
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3690038A4 (en) 2017-09-29 2021-05-19 Daiichi Sankyo Company, Limited ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN115466231B (zh) * 2022-10-23 2024-03-08 浙江大学 管道化制备3-[2-(4-吗啉基)乙氧基]丙腈的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
JPH04502469A (ja) 1988-12-22 1992-05-07 ゾマ　コーポレイション ヒンダードカップリング剤および方法
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US7049311B1 (en) 1998-08-27 2006-05-23 Spirogen Limited Pyrrolbenzodiazepines
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
NZ539395A (en) 2002-11-07 2009-01-31 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
EP3524611B1 (en) 2003-05-20 2020-12-30 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
DK1660513T5 (da) 2003-07-21 2011-07-18 Immunogen Inc CA6 antigen-specifikt, cytotoksisk konjugat og fremgangsmåder til anvendelse heraf
WO2005040170A2 (en) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
WO2005085260A1 (en) 2004-03-09 2005-09-15 Spirogen Limited Pyrrolobenzodiazepines
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
CA2927595C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1813614B1 (en) * 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
WO2007093873A1 (en) * 2006-02-13 2007-08-23 Council Of Scientific And Industrial Research Bis-pyrr0l0[2,l-c] [1, 4] benzodiazepine- anthraquinone conjugates as antitumour agents and a process for the preparation thereof
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ES2435779T3 (es) * 2007-07-19 2013-12-23 Sanofi Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
BRPI0910746B8 (pt) 2008-04-30 2021-05-25 Immunogen Inc agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica
CN104258413A (zh) 2008-04-30 2015-01-07 伊缪诺金公司 有效的偶联物和亲水性连接体
FR2939795B1 (fr) 2008-12-17 2010-12-17 Sanofi Aventis Procede de preparation d'esters actives
ES2604668T3 (es) * 2009-02-05 2017-03-08 Immunogen, Inc. Nuevos derivados de benzodiacepina
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS

Also Published As

Publication number Publication date
NI201300010A (es) 2013-05-13
CR20130035A (es) 2013-03-04
EP2598507B1 (en) 2017-05-31
US9056914B2 (en) 2015-06-16
CN103140491B (zh) 2016-08-10
EA201390162A1 (ru) 2013-11-29
MY159197A (en) 2016-12-30
SG187191A1 (en) 2013-02-28
EP2598507A1 (en) 2013-06-05
TW201208689A (en) 2012-03-01
ECSP13012404A (es) 2013-03-28
DOP2013000021A (es) 2013-04-15
ES2638520T3 (es) 2017-10-23
AU2011284339B2 (en) 2015-11-05
CO6650375A2 (es) 2013-04-15
FR2963007B1 (fr) 2013-04-05
JP2013532680A (ja) 2013-08-19
ZA201300685B (en) 2014-10-29
NZ606246A (en) 2015-04-24
UA111164C2 (uk) 2016-04-11
BR112013001978B1 (pt) 2020-03-03
CN103140491A (zh) 2013-06-05
GT201300025A (es) 2014-07-11
CA2806665A1 (en) 2012-02-02
CL2013000250A1 (es) 2013-04-12
PE20130489A1 (es) 2013-05-08
AR082341A1 (es) 2012-11-28
MX2013001069A (es) 2013-12-02
KR20130094806A (ko) 2013-08-26
FR2963007A1 (fr) 2012-01-27
JP5814366B2 (ja) 2015-11-17
US20130137659A1 (en) 2013-05-30
AU2011284339A1 (en) 2013-02-14
MA34469B1 (fr) 2013-08-01
WO2012014147A1 (en) 2012-02-02
UY33531A (es) 2012-02-29

Similar Documents

Publication Publication Date Title
BR112013001978A2 (pt) derivados de anticâncer, preparação dos mesmos e uso terapêutico dos mesmos
MY157469A (en) Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
MX2010009646A (es) Agentes terapeuticos antivirales.
EA200870421A1 (ru) Димеры производных артемизинина, их получение и их применение в терапии
MX2020010616A (es) Metodos para preparar pirrolobenzodiazepinas y conjugados dirigidos.
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
MY172750A (en) 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
ECSP18034035A (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico
UY32517A (es) Derivados de nicotinamida, su preparación y su aplicación en terapéutica
EA201792516A1 (ru) Макроциклические димеры бензодиазепина, их конъюгаты, получение и применение
BRPI1008855B8 (pt) derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
BR112012009670A2 (pt) compostos de cumarina como moduladores de receptor com utilidade terapêutica
BR112013025682A2 (pt) Compostos, composição farmacêutica, uso de um composto, combinação e dispositivo
TN2013000014A1 (en) Anticancer derivatives, preparation thereof and therapeutic use thereof
BR112012018658A2 (pt) sais farmaceuticamente aceitáveis de derivados heterocíclicos nitrogenosos - pirrolo, processo de preração e seu uso médico
BR112015012391A2 (pt) sobremesa composta láctea e os seus processo de preparação
UY29501A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/07/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2732 DE 16-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.